House of Napius is India's first line of radiation safe maternity wear using path breaking NESA technology (Non-Ionizing Electromagnetic Shielding Alternatives.
Most expectant mothers understand that carrying a child means taking extra safety measures to protect the growing life. Mothers-to-be are aware that they need to avoid certain chemicals, foods, and some beverages. Our line of radiation safe maternity wear provides an additional safeguard by shielding against radiation from cell phones, wireless routers, laptop and computers. House of Napius offers a wide range of revolutionary, radiation safe Maternity wear for the first time in India.
With a lack of choice and growing radiation concerns Founder Director, Nehal Mehta says: “Today we cannot live a gadget or appliance free lifestyle. At House of Napius, we have created a solution to block the radiation from these gadgets which are used on a daily basis such as cellphones, microwaves, laptops, scanners and ipads. We are launching our first product category of maternity wear and will be expanding into other categories such a kidswear, womenswear and menswear in the future.”
When it comes to dressing during pregnancy, comfort and style are key factors/aspects. The new range of maternity wear by House of Napius includes office wear, day wear, resort, night wear and cocktail dresses. Each garment is designed to not only protect the child, but provide unparalleled comfort and ease of use for the pregnant mother. House of Napius maternity wear is available in a multitude of colours’ and patterns and will keep your child protected all through those precious nine months.
To view the Multimedia release go to:
http://www.multivu.com/players/English/7595451-house-napius-maternity-wear-india/
Dixie®, a Georgia-Pacific brand and the leader in disposable tableware and other conveniences for busy families, today announced the creation of a social movement called “Dark for Dinner.” The movement, which launches on June 14 and will take place every Sunday for six weeks, is designed to encourage families to focus on the present and to “Be More Here.”
Dixie is asking families to remove all distractions, including electronic devices, from their dinner experience, and then share what they learned from going “Dark for Dinner” via social media using the hashtag, #DarkforDinner.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7279951-dixie-launches-dark-for-dinner-movement/
A National Safety Council public opinion poll found more than eight in 10 Americans believe cell phones are addictive, underscoring the need to help drivers kick their cell phone use habit – even hands-free. The Council is launching a national campaign, Calls Kill, to illustrate that hands-free cell phones are not risk-free, and no call is worth a life. Visit nsc.org/CallsKill for downloadable posters, infographics, videos, tip sheets and other information related to this important topic.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7398051-nsc-cell-phone-calls-kill/
Texas Instruments (TI) (NASDAQ: TXN) today announced the new SimpleLink™ ultra-low power wireless microcontroller (MCU) platform that helps customers go battery-less with energy harvesting or enjoy always-on, coin cell-powered operation for multiple years. With this industry-first technology, customers have the flexibility to develop products that support multiple wireless connectivity standards using a single-chip and identical RF design. The SimpleLink ultra-low power platform supports Bluetooth® low energy, ZigBee®, 6LoWPAN, Sub-1 GHz, ZigBee RF4CE™ and proprietary modes up to 5Mbps. This platform expands TI’s SimpleLink portfolio, the broadest, lowest power and easiest to use wireless connectivity offering in the industry for the Internet of Things (IoT). For more information, visit www.ti.com/simplelinkulp.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70647527-texas-instruments-simplelink/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
For many sports fans, it’s “that” time of the year. College and professional football season equate to prime time tailgating season. Fans seem to be tailgating more than ever as Tailgater Magazine estimates that 50 million people tailgate annually in North America.
Each year, tailgaters seem to try to compete for the biggest and best tailgates. Besides radios, blenders, and hot plates, it’s not uncommon to find big screen TVs, gaming systems, stereos, and of course, cell phone chargers at a typical tailgate this fall. All of this electronic equipment requires portable power to keep it running. Briggs & Stratton’s PowerSmart Series™ P3000 inverter generator takes tailgating to a whole new level for sports fans that require a quiet, lightweight, and fuel efficient portable generator to power all of their big game tailgating essentials.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7303151-briggs-and-stratton-powersmart-series-p3000-inverter-generator/
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
